<DOC>
	<DOCNO>NCT01995747</DOCNO>
	<brief_summary>Despite success Omalizumab neutralize free IgE blood interstitial fluid , treatment many allergic disorder remain unmet medical need . Omalizumab approve patient serum IgE level range 30-700 IU/ml . Omalizumab may effective patient much high serum IgE level , atopic dermatitis . Therefore , alternative approach target IgE-committed B cell directly inhibit synthesis IgE without bind free IgE attractive . Anti-CεmX mAb , develop Dr. TW Chang Academia Sinica , bind human mIgE+ cell , include IgE-committed lymphoblast memory B cell . Such anti-CεmX mAbs able activate B cell receptor ( BCR ) signaling , lead anergy apoptosis mIgE+ B lymphoblasts , induces ADCC Fc portion . Depletion mIgE+ B cell anti-CεmX treatment would inhibit formation IgE-producing plasma cell , result long-term attenuation IgE synthesis would eventually lead desensitized state allergic patient .</brief_summary>
	<brief_title>The Effect Anti-CεmX IgE Production</brief_title>
	<detailed_description>This study collect blood patient high serum IgE level investigate function h4b12 , humanize mAb specific mIgE+ B cell , compare effect h4B12 , Omalizumab , Rituxumab suppression IgE production number IgE-producing plasma cell . These blood specimen collect 50 patient atopic dermatitis urticaria high serum IgE level . Fountain Biopharma carry follow two vitro assay measure efficacy h4B12 : - IgE ELISA determine concentration IgE . - IgE ELISPOTto determine number IgE-producing plasma cell .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female subject age ≥ 18 year Clinical diagnosis atopic dermatitis chronic urticaria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>IgE</keyword>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>antibody</keyword>
	<keyword>allergy</keyword>
</DOC>